1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related)
Key Takeaways
- BRCA1 and BRCA2 are autosomal dominant high-penetrance genes; BRCA1 skews toward higher ovarian cancer risk and more triple-negative breast cancers, while BRCA2 more often associates with ER-positive breast cancer and male breast, prostate, and pancreatic risks
- NCCN Genetic/Familial High-Risk Assessment guidelines frame testing criteria, age-triggered MRI/mammography, and risk-reducing salpingo-oophorectomy (RRSO) timing discussions for pathogenic variant carriers
- PARP inhibitors exploit homologous recombination deficiency in BRCA-related cancers and are a key management concept genetic counselors should recognize when discussing treatment implications of a positive result
- PALB2 is a high-risk breast cancer gene; ATM and CHEK2 are typically moderate-risk genes with gene-specific counseling that should not be collapsed into a BRCA-equivalent script
- Risk-reducing mastectomy and RRSO counseling addresses residual risk, fertility/menopause, cascade testing, and psychosocial readiness—not only lifetime risk percentages
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related)
Quick Answer: BRCA1/BRCA2 pathogenic variants cause autosomal dominant hereditary breast and ovarian cancer (HBOC) with gene-specific tumor spectra. Counsel using NCCN Genetic/Familial High-Risk Assessment concepts for testing, MRI/mammography, and RRSO timing; distinguish high-risk genes (BRCA1/2, PALB2) from moderate-risk genes (ATM, CHEK2). Positive results can open PARP-inhibitor treatment pathways in oncology.
Domain 1C cancer genetics items expect you to recognize features, natural history, surveillance, risk reduction, diagnostic strategy, and inheritance—not to memorize unpublished point estimates. Quote guideline families (commonly NCCN) and well-established ranges; avoid inventing false precision.
Why HBOC Matters on the CGC Exam
Hereditary breast and ovarian cancer is the most frequently tested adult-onset cancer genetics vignette. Cases may start as a young breast cancer diagnosis, a ovarian/fallopian tube/primary peritoneal cancer, male breast cancer, pancreatic cancer with a suggestive pedigree, or cascade testing after a relative’s pathogenic variant. Your job is to map phenotype → gene differential → testing strategy → management implications for the consultand and relatives.
Inheritance and Biology
| Feature | Teaching point |
|---|---|
| Inheritance | Autosomal dominant predisposition with incomplete penetrance and variable expressivity |
| Gene class | Tumor suppressors in homologous recombination (HR) DNA repair |
| Knudson logic | Germline “first hit”; somatic loss of the second allele in tumor tissue |
| Founder variants | Notable in Ashkenazi Jewish populations (BRCA1 185delAG, 5382insC; BRCA2 6174delT)—still confirm with full gene analysis when indicated |
Pathogenic variants in BRCA1 or BRCA2 substantially elevate lifetime risks of female breast and ovarian cancers relative to population baselines. Exact percentages vary by study, ascertainment, and modifier factors; board-level teaching uses elevated, gene-specific ranges and points patients to current NCCN tables rather than a single memorized number.
BRCA1 vs BRCA2: Phenotype Differences
| Dimension | BRCA1 | BRCA2 |
|---|---|---|
| Female breast cancer | High risk; enrichment for triple-negative (ER−/PR−/HER2−) tumors | High risk; more often hormone receptor–positive histology |
| Ovarian / fallopian / peritoneal | Generally higher ovarian cancer risk than BRCA2 | Elevated ovarian risk, typically lower than BRCA1 on average |
| Male breast cancer | Elevated vs population, but more characteristic of BRCA2 | Classic association; male breast cancer is a testing red flag |
| Prostate cancer | Increased risk reported | More consistently emphasized; earlier/aggressive disease possible |
| Pancreatic cancer | Increased | Increased (often highlighted in counseling) |
| Other | Melanoma sometimes discussed | Melanoma associations also discussed in literature |
Exam trap: Do not treat BRCA1 and BRCA2 as interchangeable scripts. Histology, sex-specific cancers, and RRSO timing nuances differ. Both remain high-penetrance HBOC genes requiring structured surveillance and risk-reduction counseling.
Related Genes: PALB2, ATM, CHEK2 (High-Level)
Modern hereditary cancer panels expand beyond BRCA1/2. Counselors must stratify by risk magnitude and organ-specific implications.
| Gene | Approximate risk tier (conceptual) | Counseling anchors |
|---|---|---|
| PALB2 | High-risk breast cancer gene; ovarian risk less dominant than BRCA1 | Partner-and-localizer of BRCA2 in HR; breast MRI often considered; risk-reducing mastectomy may be discussed based on personal/family history and guidelines |
| ATM | Moderate breast cancer risk | Avoid collapsing into BRCA-equivalent RRSO defaults; heterozygous counseling differs from biallelic ataxia-telangiectasia |
| CHEK2 | Moderate breast cancer risk (variant-dependent) | Commonly includes discussion of breast surveillance intensification; ovarian risk generally not managed like BRCA1 |
| Other HR-related genes | Panel-dependent (BARD1, RAD51C/D, BRIP1, etc.) | Gene-specific ovarian vs breast emphasis—use current NCCN gene pages |
Biallelic pathogenic variants in some of these genes cause rare recessive syndromes (e.g., Fanconi anemia pathway for certain BRCA2/PALB2 genotypes; ataxia-telangiectasia for ATM). When counseling a heterozygous adult, briefly note reproductive implications if both partners could be carriers.
Diagnostic / Testing Strategy
- Phenotype- and pedigree-driven pretest counseling: cancer types, ages, pathology, ancestry, prior testing in the family.
- Prefer testing an affected relative first when feasible; if unavailable, test the consultand with clear limitations.
- Choose multi-gene panel vs targeted known-familial variant testing based on whether a familial pathogenic variant is already identified.
- Interpret VUS cautiously—do not change surgical plans based on VUS alone.
- Arrange cascade testing for relatives when a pathogenic/likely pathogenic variant is found.
Ashkenazi Jewish ancestry may prompt discussion of founder-variant strategies historically, but contemporary practice often still favors broader analysis when clinical criteria are met—follow current laboratory and guideline context.
Surveillance and Risk Reduction (NCCN-Style Concepts)
NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic guidelines (and related breast cancer screening guidelines) organize age to start annual breast MRI, mammography, clinical exams, and discussions of risk-reducing mastectomy and risk-reducing salpingo-oophorectomy (RRSO).
| Intervention | Counseling themes |
|---|---|
| Breast MRI ± mammography | Earlier start than average-risk screening for high-risk gene carriers; MRI sensitivity for dense breasts; false-positive anxiety |
| Risk-reducing mastectomy | Greatest breast cancer risk reduction; does not eliminate residual risk entirely; reconstruction, body image, timing relative to childbearing |
| RRSO | Major ovarian/fallopian cancer risk reduction for BRCA1/2; timing often gene- and age-informed (commonly discussed earlier for BRCA1 than BRCA2 in guideline tables); surgical menopause, bone/cardiovascular health, HRT nuances, fertility |
| Salpingectomy strategies | Emerging/interval concepts may appear in counseling literature—distinguish established RRSO recommendations from evolving protocols |
| Pancreatic surveillance | Considered in selected BRCA2 (and other) carriers with additional risk factors per specialty guidelines—not universal for every HBOC gene |
Do not invent exact unpublished percentages on the exam essay of counseling; say “substantially elevated,” cite the guideline family, and individualize.
PARP Inhibitors and Oncology Management Concepts
Poly(ADP-ribose) polymerase (PARP) inhibitors exploit synthetic lethality in homologous recombination–deficient cells. For genetic counselors, the board-relevant points are:
- A germline BRCA1/2 (and some other HR gene) finding can change treatment eligibility discussions with the oncology team.
- Indications evolve (breast, ovarian, prostate, pancreatic contexts appear in oncology practice).
- Counseling separates hereditary risk management for the patient and family from tumor-directed therapy, while explaining why germline results matter to both.
You are not prescribing; you are ensuring the patient understands why germline testing was ordered and how results may open targeted options alongside cascade prevention.
Putting It Together in a Counseling Session
- Collect pathology (especially triple-negative breast cancer, high-grade serous ovarian) and pedigree.
- Explain autosomal dominant inheritance and incomplete penetrance in plain language.
- Contrast BRCA1 vs BRCA2 tumor spectra when relevant; introduce PALB2/moderate-risk genes if panel testing is planned.
- Preview management: intensified breast imaging, RRSO/mastectomy decisions, possible PARP-inhibitor relevance.
- Plan disclosure, psychosocial support, and relative cascade testing.
HBOC fluency is the foundation for the next sections on Lynch/polyposis and rarer high-penetrance syndromes.
Compared with BRCA1-associated breast cancers, BRCA2-associated breast cancers are more often which of the following?
A pathogenic BRCA1 variant is identified in a premenopausal patient. Which counseling theme best reflects NCCN-style risk-reduction discussion for ovarian cancer risk?
Which statement best distinguishes PALB2 from moderate-risk genes such as CHEK2 in hereditary breast cancer counseling?
Why might oncology teams care about a germline BRCA1/2 pathogenic variant beyond cascade family testing?